Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Janssen-Cilag International N.V
Femme et Homme Max 99 ans
Janssen-Cilag International N.V
MAJ Il y a 4 ans
A Phase 2, Multicentre, Randomised, Open-Label, Parallel Group Study to Evaluate the Safety and Efficacy of VELCADE® in combination with Dexamethasone or VELCADE® in combination with Dexamethasone and Cyclophosphamide or VELCADE® in combination with Dexamethasone and Lenalidomide in Subjects with Multiple Myeloma who are Refractory to or Have Relapsed / progressed after Primary Therapy for Multiple Myeloma and have achieved stable disease after 4 cycles of VELCADE®/Dexamethasone therapy
The primary objective is to assess the efficacy of adding either Cyclophosphamide or Lenalidomide to the combination of Velcade® (bortezomib) and Dexamethasone in subjects with multiple myeloma who ar...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Janssen-Cilag International N.V
MAJ Il y a 4 ans
A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants
The primary efficacy objective is to demonstrate that rivaroxaban is superior to placebo for reducing the risk of the primary composite outcome as defined by objectively confirmed symptomatic lower ex...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Janssen-Cilag International N.V
MAJ Il y a 4 ans
A Randomized Double-blind study of Ustekinumab in Pediatric Subjects with Crohn's Disease
- Evaluate the pharmacokinetics (PK) of ustekinumab in subjects from 2 through <18 years old and determine if it is similar to that observed in adults with moderately to severely active CD. - Assess ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Janssen-Cilag International N.V
MAJ Il y a 4 ans
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients with High-risk Smoldering Multiple Myeloma
The primary objective of the study is to demonstrate that siltuximab will delay progression of high-risk SMM as measured by the 1 year progression-free survival (PFS) rate.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Janssen-Cilag International N.V
MAJ Il y a 4 ans
Investigation of the safety, tolerability, and efficacy of JNJ-40411813 as an add-on treatment to an antidepressant in patients with depression with anxiety symptoms
To evaluate the efficacy, as assessed by the change from baseline on a 6-item subscale derived from the Hamilton Anxiety Scale (HAM-A6), and overall safety and tolerability of treatment with adjunctiv...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Janssen-Cilag International N.V
MAJ Il y a 4 ans
An Open-label Prospective Trial to Explore the Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Subjects With Schizophrenia
The primary objective of this study is to explore the efficacy, based on total Positive and Negative Syndrome Scale (PANSS) score, of flexibly dosed paliperidone ER in subjects with schizophrenia prev...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Janssen-Cilag International N.V
MAJ Il y a 4 ans
A Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Flexibly-Dosed Extended-Release Paliperidone Compared with Flexibly-Dosed Quetiapine and Placebo in the Treatment of Acute Manic and Mixed Episodes Associated with Bipolar I Disorder
The primary objectives of the study are to demonstrate the antimanic efficacy and to assess the safety of flexibly dosed paliperidone extended release (ER) compared with placebo during 3 weeks of trea...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Janssen-Cilag International N.V
MAJ Il y a 4 ans
A study to investigate the safety of the drugs topiramate and levetiracetam in treating children recently diagnosed with epilepsy
The primary objective is to evaluate the effects of topiramate monotherapy compared with levetiracetam, another standard antiepileptic drug (AED), as monotherapy for new-onset or recent-onset epilepsy...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme
Entre 18 ans
et 99 ans
Janssen-Cilag International N.V
MAJ Il y a 4 ans
Janssen-Cilag CR010519 : Essai de phase 2 évaluant l’efficacité d’un traitement par bortezomib, chez des patients ayant un myélome multiple ayant répondu à un précédant traitement à base de bortezomib. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
L’objectif de cet essai est d’évaluer l’efficacité et la tolérance d’un traitement par bortezomib, chez des patients ayant un myélome multiple ayant répondu à un précédant traitement à base de bortezo...
Pays
France
Organes
Myélomes
Spécialités
Chimiothérapie
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Janssen-Cilag International N.V
MAJ Il y a 4 ans
An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants greater than 6 to less than 12 Years of Age
To evaluate the efficacy and safety of ustekinumab in pediatric subjects aged ≥6 through <12 years with moderate to severe chronic plaque psoriasis.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
1
2
3
4
5
6
7
8
9
10
Suivant